www.cerevel.com
Open in
urlscan Pro
34.73.75.90
Public Scan
Submitted URL: http://www.cerevel.com/
Effective URL: https://www.cerevel.com/
Submission: On October 11 via api from US — Scanned from DE
Effective URL: https://www.cerevel.com/
Submission: On October 11 via api from US — Scanned from DE
Form analysis
0 forms found in the DOMText Content
Skip to content Cerevel * About CerevelAbout Cerevel * Unraveling the mysteries of the brain * Leadership team * Partnerships * Our ProgramsOur Programs * Emraclidine * Darigabat * Tavapadon * CVL-871 * Our ScienceOur Science * Our scientific strategy * Our pipeline * Investors & MediaInvestors & Media * Overview * News & EventsNews & Events * News & Announcements * Events * Presentations * StockStock * Stock quote & chart * Historic price lookup * Investment calculator * Analyst coverage * FinancialsFinancials * SEC filings * Annual reports * Quarterly results * GovernanceGovernance * Documents Charters * Leadership team * Committee Composition * ResourcesResources * Investor FAQs * Email alerts * Investor & Media Contact * CareersCareers * Working at Cerevel Therapeutics * Open Positions * Fellowship Programs * Contact Us UNRAVELING THE MYSTERIES OF THE BRAIN TO TREAT NEUROSCIENCE DISEASES Cerevel Therapeutics is working relentlessly to find paths through complexity in an effort to bring real progress and new treatment options to people living with some of the most devastating neuroscience diseases. TRANSFORMING WHAT IS POSSIBLE IN NEUROSCIENCE We are a team of experts purpose-built to make intentional, rigorously evaluated decisions that are designed to deliver innovation in neuroscience. Learn more UNLOCKING NEW TREATMENT OPPORTUNITIES BY UNDERSTANDING HOW DEFICITS IN NEUROCIRCUITRY DRIVE THE DEVELOPMENT OF SYMPTOMS Devastating and life-threatening neuroscience diseases represent one of the greatest opportunities of our time to help the hundreds of millions of people affected worldwide. Addressing these underserved areas and communities is the focus of our research and development efforts. Learn more OUR LATEST NEWS * Cerevel Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference September 6, 2022 * Cerevel Therapeutics Announces Pricing of $300 Million Private Offering of Convertible Senior Notes and Concurrent $254 Million Public Offering of Common Stock August 12, 2022 * Cerevel Therapeutics Announces Pricing of $254 Million Public Offering of Common Stock and Concurrent $300 Million Private Offering of Convertible Senior Notes August 12, 2022 Read More Cerevel * About CerevelAbout Cerevel * Unraveling the mysteries of the brain * Leadership team * Partnerships * Our ProgramsOur Programs * Emraclidine * Darigabat * Tavapadon * CVL-871 * Our ScienceOur Science * Our scientific strategy * Our pipeline * Investors & MediaInvestors & Media * Overview * News & EventsNews & Events * StockStock * FinancialsFinancials * GovernanceGovernance * ResourcesResources * CareersCareers * Working at Cerevel Therapeutics * Open Positions * Fellowship Programs * Contact Us * Facebook * Twitter * LinkedIn * YouTube Cerevel * Terms of Use * Privacy Policy * FCOI * Early Access Program (EAP) Policy © 2022 Cerevel Therapeutics CEREVEL and the CEREVEL logo are trademarks of Cerevel Therapeutics. All Rights Reserved. You are now leaving cerevel.com, a website provided by Cerevel Therapeutics. The content displayed on external websites is not controlled by Cerevel, and Cervel assumes no responsibility for the information or statements on external websites. Cancel OK